摘要
目的:观察羟苯磺酸钙联合缬沙坦治疗免疫球蛋白A(IgA)肾病的疗效。方法:58例IgA肾病患者随机分为观察组和对照组,对照组给予缬沙坦160 mg·d-1,观察组给予羟苯磺酸钙500 mg,tid,联合缬沙坦160 mg·d-1,6个月后观察血压、血纤维蛋白原(FIB)、尿素氮(BUN)、血清肌酐(Scr)、血尿酸(UA)、24 h尿蛋白定量(Upro)等指标的变化情况。结果:治疗后两组UA、Upro较治疗前均有所下降,有统计学意义(P<0.05或0.01)。观察组Upro由(1.48±0.84)g/24 h降为(0.41±0.22)g/24 h,与对照组相比有统计学意义(P<0.05)。治疗后观察组BUN、Scr、FIB显著下降(P<0.05),但对照组相比差异无统计学意义(P>0.05)。结论:羟苯磺酸钙联合缬沙坦能有效降低IgA肾病患者尿蛋白量,改善其肾功能。
Objective： To observe the clinical efficacy of calcium dobesilate combined with valsartan in the treatment of IgA nephropathy. Methods： Totally 58 cases of IgA nephropathy were randomly divided into the treatment group and the control group. The control group enrolled 29 cases given valsartan 160 mg ·d-1. The treatment group included 29 cases treated with calcium dobesiiate 500 mg · time-1, tid, and valsartan 160 mg·d-1. After 6 months, the following indicators were observed, such as blood pressure, fibrinogen, urea nitrogen, serum creatinine,blood uric acid, and 24-hour urinary （Upro）. Results： After 6 months, UA and Upro of the two groups were significantly declined than those before the treatment （the control group P 〈 0.05, the treatment group P 〈 0.01 ）. Upro of the treatment group was declined from （ 1.48 ± 0.84） g/24h to （0.41 ± 0.22） g/24h, and there was statistical significance compared with the control group （ P 〈 0.05 ）. BUN, Scr and FIB were decreased significantly （ P 〈 0.05 ）, while no significant change showed in those in the control group after the treatment： Conclusion： Calcium dobesilate combined valsartan can effectively reduce Upro and improve renal function in IgA nephropathy.
出处
《中国药师》
CAS
2014年第2期247-249,共3页
China Pharmacist
